Transplant Genomics Launches OmniGraf™, the Only Combination Biomarker Panel That Provides the Earliest Indication of Rejection in Kidney Transplant Recipients
27 Septembre 2021 - 7:00AM
Business Wire
Transplant Genomics (“TGI”), the transplant rejection
diagnostics company committed to improving organ transplant
outcomes worldwide, is pleased to introduce OmniGraf™, which
combines the TruGraf® blood gene expression test and
Viracor TRAC® donor-derived cell-free DNA assays. For renal
transplant recipients, OmniGraf™ Kidney represents the first
diagnostic tool that combines cell free DNA and gene expression
data. When combined with TGI’s proprietary technology and machine
learning, the test offers patients the earliest and most accurate
view of kidney transplant rejection.
Through gene expression from TruGraf® and the
donor-derived cell-free DNA of the Viracor TRAC® test,
Omnigraf™ Kidney provides a comprehensive view of both
subclinical acute rejection and clinical acute rejection with the
highest positive predictive value (PPV) and negative predictive
value (NPV) available in a diagnostic panel. OmniGraf™
requires 6 milliliters (mL) of blood, which can be obtained via a
routine phlebotomy draw, greatly simplifying sample collection and
logistics.
Commenting on the collaboration, Eurofins CEO, Dr. Gilles
Martin; “We are very pleased to have collaborated with Northwestern
University on this highly innovative test which will facilitate
speed and accuracy in rejection detection, and, critically, improve
patient outcomes. This partnership highlights the Group’s
commitment to innovation and the advancement of science to improve
the health and safety of our world. We look forward to the roll out
of this test to medical institutions globally, so transplant
patients and healthcare professionals can benefit from strengthened
insights to inform treatment decisions.”
To learn more, please visit:
https://www.eurofins.com/media-centre/press-releases/2021-09-27/
About Eurofins’ Transplant Genomics, Inc.
Transplant Genomics, Inc. ("TGI") is a personalized diagnostics
company committed to improving organ transplant outcomes worldwide
through innovative tests that detect early signs of graft injury,
differentiate among actionable causes, and enable the optimization
of therapy. Working alongside the transplant community and within
the Eurofins family, TGI is commercializing a suite of tests
enabling diagnoses and prediction of transplant recipient immune
status. TGI was acquired by Eurofins Scientific in 2019.
Learn more about Eurofins’ Transplant Genomics at
https://transplantgenomics.com/
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With 55,000 staff across a network of
900 laboratories in over 50 countries, Eurofins’ companies offer a
portfolio of over 200,000 analytical methods. Eurofins Shares are
listed on Euronext Paris Stock Exchange.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210926005018/en/
Nicholas Grund NicholasGrund@eurofinsUS.com
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024